Nurix Therapeutics, Inc. NRIX

US Biotechnology

$15.97 ▼ -1.05% ($-0.17)

🔥 High Short Interest

Open $16.16

Prev Close $16.14

Day Range $15.89 – $16.77

52W Range $11.67 – $28.23

Market Cap $1.76B

P/E (TTM) 6.01

Beta 1.82

EPS (TTM) $2.31

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-07-24
Shares Out.	109,250,000
Website	nurixtx.com ↗
Phone	14156605320
Employees	357
Revenue	$673.1M
Gross Profit	$673.1M
Net Income	$549.8M
Free Cash Flow	$369.8M
Total Assets	$1.20B
Total Liabilities	$227.0M
Equity	$968.3M

About Nurix Therapeutics, Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Nurix Therapeutics, Inc. is a publicly traded company under the ticker symbol NRIX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.